JP2005516996A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005516996A5 JP2005516996A5 JP2003565503A JP2003565503A JP2005516996A5 JP 2005516996 A5 JP2005516996 A5 JP 2005516996A5 JP 2003565503 A JP2003565503 A JP 2003565503A JP 2003565503 A JP2003565503 A JP 2003565503A JP 2005516996 A5 JP2005516996 A5 JP 2005516996A5
- Authority
- JP
- Japan
- Prior art keywords
- residue
- xaa
- pharmaceutical composition
- threonine
- serine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 18
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 18
- 125000000539 amino acid group Chemical group 0.000 claims 13
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 13
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 10
- 229940088597 hormone Drugs 0.000 claims 9
- 239000005556 hormone Substances 0.000 claims 9
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 8
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical group OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 7
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 7
- 239000000126 substance Substances 0.000 claims 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 6
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 6
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 6
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 5
- 230000000903 blocking effect Effects 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
- 229960001230 asparagine Drugs 0.000 claims 4
- 235000009582 asparagine Nutrition 0.000 claims 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 3
- 230000001483 mobilizing effect Effects 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 229920002527 Glycogen Polymers 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940096919 glycogen Drugs 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/072,419 US6852693B2 (en) | 2002-02-07 | 2002-02-07 | Compositions and methods for promoting lipid mobilization in humans |
| PCT/US2003/003800 WO2003066080A1 (en) | 2002-02-07 | 2003-02-07 | Compositions and methods for promoting lipid mobilization, glycogen mobilization, or both, in humans |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005516996A JP2005516996A (ja) | 2005-06-09 |
| JP2005516996A5 true JP2005516996A5 (enExample) | 2006-03-30 |
Family
ID=27732307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003565503A Withdrawn JP2005516996A (ja) | 2002-02-07 | 2003-02-07 | 脂質可動化、グリコーゲン可動化、またはその両方をヒトにおいて促進するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6852693B2 (enExample) |
| EP (1) | EP1480668A1 (enExample) |
| JP (1) | JP2005516996A (enExample) |
| AU (1) | AU2003210923A1 (enExample) |
| CA (1) | CA2474203A1 (enExample) |
| WO (1) | WO2003066080A1 (enExample) |
| ZA (1) | ZA200406715B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6852693B2 (en) * | 2002-02-07 | 2005-02-08 | Blm Group | Compositions and methods for promoting lipid mobilization in humans |
| WO2005067912A1 (en) * | 2004-01-02 | 2005-07-28 | Washington University In St. Louis | Method of intentionally, noninvasively, therapeutically modulating fat in a living mammal |
| US20050222040A1 (en) * | 2004-04-05 | 2005-10-06 | Blm Group, Inc. | Vertebrate peptide modulators of lipid metabolism |
| JP4688483B2 (ja) * | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
| WO2010051347A1 (en) * | 2008-10-31 | 2010-05-06 | David Sheikh-Hamad | A method for cardioprotection |
| CN102438580B (zh) * | 2009-02-06 | 2015-06-17 | 加利福尼亚大学董事会 | 钙结合剂诱导毛发生长和/或甲生长 |
| EP3119416B1 (en) | 2015-03-26 | 2017-12-20 | Mutlu, Oguz | Therapeutic use of adipokinetic hormone/red pigment-concentrating hormone (akh/rpch) family of peptides |
| TR201712479A2 (tr) | 2017-08-22 | 2019-05-21 | Oguz Mutlu | Adi̇poki̇neti̇k hormon/kirmizi pi̇gment-konsantre edi̇ci̇ hormon (akh/rpch) pepti̇t ai̇lesi̇ni̇n yeni̇ terapöti̇k kullanimlari |
| KR102380291B1 (ko) * | 2020-06-15 | 2022-03-29 | 대한민국 | 풀무치 추출물을 포함하는 비만 예방 또는 치료용 조성물 |
| KR102380290B1 (ko) * | 2020-06-15 | 2022-03-29 | 대한민국 | 아메리카왕거저리 유충 추출물을 포함하는 비만 예방 또는 치료용 조성물 |
| GB202215797D0 (en) | 2022-10-25 | 2022-12-07 | Solasta Bio Ltd | Insect neuropeptide analogues |
| US12245588B1 (en) | 2023-10-23 | 2025-03-11 | Solasta Bio Limited | Insect neuropeptides 2 |
| US12356995B2 (en) | 2023-10-23 | 2025-07-15 | Solasta Bio Limited | Insect neuropeptides 9 |
| US12281143B1 (en) | 2023-10-23 | 2025-04-22 | Solasta Bio Limited | Insect neuropeptides 1 |
| US12302908B2 (en) | 2023-10-23 | 2025-05-20 | Solasta Bio Limited | Insect neuropeptides 4 |
| US12245596B1 (en) | 2023-10-23 | 2025-03-11 | Solasta Bio Limited | Insect neuropeptides 8 |
| EP4570072A3 (en) * | 2023-10-23 | 2025-07-02 | Solasta Bio Limited | Insect neuropeptides 8 |
| US12279621B1 (en) | 2023-10-23 | 2025-04-22 | Solasta Bio Limited | Insect neuropeptides 3 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260601A (en) | 1979-10-23 | 1981-04-07 | Nyegaard & Co. A/S | Chemical compounds |
| US4328134A (en) | 1980-05-06 | 1982-05-04 | Schally Andrew Victor | Anorexigenic peptides |
| US4464356A (en) | 1982-05-07 | 1984-08-07 | Mordes John P | Anorexigenic composition and method |
| US4489059A (en) | 1982-05-07 | 1984-12-18 | Rossini Aldo A | Anorexigenic composition and method |
| US4891219A (en) | 1986-03-14 | 1990-01-02 | Aphton Corporation | Method for immunization against and treatment of infection by ectoparasites and endoparasites |
| GB8806471D0 (en) | 1988-03-18 | 1988-04-20 | Tisdale M J | Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours |
| US5616311A (en) * | 1991-01-15 | 1997-04-01 | Hemosphere, Inc. | Non-crosslinked protein particles for therapeutic and diagnostic use |
| FR2710340B1 (fr) | 1993-09-22 | 1995-12-15 | D Hinterland Lucien Dussourd | Dérivés peptidiques de l'alpha-MSH et leur application . |
| FR2767135B1 (fr) | 1997-08-06 | 2002-07-12 | Genset Sa | Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes |
| US6852693B2 (en) * | 2002-02-07 | 2005-02-08 | Blm Group | Compositions and methods for promoting lipid mobilization in humans |
-
2002
- 2002-02-07 US US10/072,419 patent/US6852693B2/en not_active Expired - Fee Related
-
2003
- 2003-02-07 AU AU2003210923A patent/AU2003210923A1/en not_active Abandoned
- 2003-02-07 CA CA002474203A patent/CA2474203A1/en not_active Abandoned
- 2003-02-07 JP JP2003565503A patent/JP2005516996A/ja not_active Withdrawn
- 2003-02-07 WO PCT/US2003/003800 patent/WO2003066080A1/en not_active Ceased
- 2003-02-07 EP EP03737707A patent/EP1480668A1/en not_active Withdrawn
-
2004
- 2004-06-16 US US10/869,768 patent/US7314865B2/en not_active Expired - Fee Related
- 2004-08-24 ZA ZA200406715A patent/ZA200406715B/xx unknown
-
2007
- 2007-10-19 US US11/975,735 patent/US8067363B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005516996A5 (enExample) | ||
| JP2005505579A5 (enExample) | ||
| ES2302390T3 (es) | Analogos de glp-1. | |
| JP2003501022A5 (enExample) | ||
| JPH05163298A (ja) | 新規ポリペプチドおよびこれを用いる抗hiv剤 | |
| JP2005519059A5 (enExample) | ||
| JP2007001987A5 (enExample) | ||
| JP2011511753A5 (enExample) | ||
| RU2010103995A (ru) | Бифункциональные слитые белки альфа-меланоцитостимулирующего гормона (альф-msh) и атриального натрийуретического белка (anp) и их применение при гипертонии и остром повреждении почек | |
| RU2016120641A (ru) | Новые полипептиды | |
| WO2008039483A3 (en) | Modified self-assembling peptides | |
| JP2010510315A5 (enExample) | ||
| PT1290013E (pt) | Derivados dos peptidos apo-ai/aii | |
| JP2004521123A5 (enExample) | ||
| CN1096515A (zh) | 新型肽 | |
| JP2006514820A5 (enExample) | ||
| JP2004505640A5 (enExample) | ||
| ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
| JP2006503088A5 (enExample) | ||
| AU671989B2 (en) | Treatment of tropical spastic paresis with peptide T | |
| WO2002068608A3 (en) | Sulfated ccr5 peptides for hiv-1 infection | |
| JP2003522185A5 (enExample) | ||
| JP2008517998A5 (enExample) | ||
| MY113407A (en) | Tri-, tetra-, penta-, and polypeptides and their therapeutic use as an antidepressant agent | |
| JP2006507328A5 (enExample) |